logo
Twitter
Discord
Email
logo
Ironwood Pharmaceuticals, Inc.

Ironwood Pharmaceuticals, Inc.

NASDAQ•IRWD
CEO: Mr. Thomas A. McCourt
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Listing Date: 2010-02-03
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
Contact Information
100 Summer Street, Suite 2300, Boston, MA, 02110, United States
617-621-7722
www.ironwoodpharma.com
Market Cap
$732.05M
P/E (TTM)
25.6
33.1
Dividend Yield
--
52W High
$5.78
52W Low
$0.53
52W Range
76%
Rank46Top 59.5%
3.5
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 3.5 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025

Financial Dashboard

Q3 2025 Data

Revenue

$122.06M+33.27%
4-Quarter Trend

EPS

$0.25+996.49%
4-Quarter Trend

FCF

$47.58M+382.13%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Nine Month Profitability Swing Nine-month net income swung $26.3M to profit, reversing prior period net loss of $(1.4)M.
Strong Third Quarter Income Q3 net income reached $40.1M USD, significantly exceeding $3.6M recognized in the comparable 2024 period.
Cash Position Improvement Cash and equivalents ended period at $140.4M; stockholders' deficit improved to $(264.2)M balance.
R&D Expense Reduction Total R&D expenses decreased $12.8M for nine months due to pipeline prioritization efforts.

Risk Factors

Intellectual Property Litigation Ferring filed IP lawsuit regarding VectivBio assets; established $7.5M litigation contingency reserve.
Apraglutide Regulatory Delay Apraglutide development requires confirmatory Phase III trial, delaying potential NDA submission timeline.
Debt Maturity Schedule $200.0M principal 2026 Convertible Notes debt obligation matures in June 2026 timeframe.

Outlook

Apraglutide Trial Planning Plan to align with FDA on apraglutide confirmatory Phase III trial design during Q4 2025 period.
Initiate Phase III Trial Expect initiation of apraglutide confirmatory Phase III trial in first half of 2026, subject to alignment.
Explore Strategic Alternatives Actively exploring strategic alternatives for company assets, engagement with Goldman Sachs LLC confirmed.

Peer Comparison

Revenue (TTM)

NeoGenomics, Inc.NEO
$709.16M
+10.1%
Ironwood Pharmaceuticals, Inc.IRWD
$338.99M
-10.4%
Lifecore Biomedical, Inc.LFCR
$135.27M
+5.3%

Gross Margin (Latest Quarter)

Ironwood Pharmaceuticals, Inc.IRWD
100.0%
+32.6pp
Fennec Pharmaceuticals Inc.FENC
94.7%
+14.2pp
CVRx, Inc.CVRX
86.8%
+3.6pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
IRWD$732.05M25.6-9.5%151.0%
NEO$330.97M-2.9-13.0%29.8%
LFCR$307.97M-9.5-232.8%58.5%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
10.5%
Steady Growth
4Q Net Income CAGR
160.9%
Profitability Improved
Cash Flow Stability
75%
Volatile Cash Flow

Research & Insights

Next earnings:Feb 26, 2026
|
EPS:$0.02
|
Revenue:-
Reports
All Years
  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Nov 10, 2025|
    Revenue: $122.06M+33.3%
    |
    EPS: $0.25+996.5%
    Beat
  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 11, 2025|
    Revenue: $85.24M-9.7%
    |
    EPS: $0.15-2877.8%
    Beat
  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 12, 2025|
    Revenue: $41.14M-45.1%
    |
    EPS: $-0.23+771.2%
    Miss
  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Mar 31, 2025|
    Revenue: $351.41M-20.6%
    |
    EPS: $0.01+100.1%
    Miss
  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Nov 7, 2024|
    Revenue: $91.59M-19.5%
    |
    EPS: $0.02-76.8%
    Miss
  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 8, 2024|
    Revenue: $94.40M-12.1%
    |
    EPS: $-0.01-99.9%
    Miss
  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 9, 2024|
    Revenue: $74.88M-28.0%
    |
    EPS: $-0.03-108.8%
    Miss
  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Feb 16, 2024|
    Revenue: $442.74M+7.8%
    |
    EPS: $-6.45-670.8%
    Miss